Boothbay Fund Management, LLC Krystal Biotech, Inc. Put Options Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $14.3 Million - $17.1 Million	-93,100 Reduced 90.56%	9,700 $1.78 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $388,836 - $645,660	3,600 Added 3.63%	102,800 $18.3 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $7.88 Million - $10.5 Million	82,100 Added 480.12%	99,200 $12.3 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $1.65 Million - $1.98 Million	15,200 Added 800.0%	17,100 $1.98 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $149,112 - $247,608	1,900 New	1,900 $223,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $890,274 - $1.13 Million	14,100 Added 83.43%	31,000 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $1.1 Million - $1.39 Million	16,900 New	16,900 $1.18 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $1.15 Million - $2.55 Million	-28,900 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.5 Million - $2.07 Million	28,900 New	28,900 $1.51 Million

303

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.1B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.